Results 111 to 120 of about 1,634 (161)

Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2. [PDF]

Front Immunol
Guo H, Wang H, Wu S, Lin H, Wang G, Pu Q.   +5 more
europepmc   +1 more source

Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. [PDF]

Front Pediatr
Tonetto S, Cason C, Fasiolo E, Dal Cin M, Cozzi G, Giangreco M, Zappetti C, Nider S, Amaddeo A, Comar M, Travan L.   +10 more
europepmc   +1 more source

Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis. [PDF]

Lancet Reg Health Eur
Perramon-Malavez A, Chiaretti A, Coma E, Craiu M, Foster S, Leonard P, Marlow R, Thors V, Martínez-Marcos M, Mendioroz J, Vila J, Creus-Costa A, Prats C, Roland D, Soriano-Arandes A, Williams TC, Buonsenso D.   +16 more
europepmc   +1 more source

Nirsevimab in Infants: The Cost of Changing the Paradigm

Mathews Journal of Pediatrics
openaire   +1 more source

The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity. [PDF]

Virus Evol
Cordela S, Harari J, Moirangthem R, Khaleafi R, Kladnitsky O, Duran D, Grunewald M, Bar-On Y.   +7 more
europepmc   +1 more source

RSV Prevention Products and Severe RSV-Associated Disease Among Infants.

JAMA Netw Open
Bennett JC, Bevers E, Chronister S, McHugh A, Choudry M, Huynh M, Englund JA, Lindquist S, Holshue ML.   +8 more
europepmc   +1 more source

RSV Prophylaxis in Neonates: Implementation and Parental Acceptance during the First RSV Season in Germany. [PDF]

Geburtshilfe Frauenheilkd
Schouten ES, Kraft AS, Delius MV, Ellenbach N, Flemmer AW, Hertlein L, Kehl S, Mahner S, Starrach T.   +8 more
europepmc   +1 more source

Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.

JAMA
Jabagi MJ, Bertrand M, Gabet A, Kolla E, Olié V, Zureik M.   +5 more
europepmc   +1 more source

Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial. [PDF]

J Pediatric Infect Dis Soc
Mori M, Leach S, Learoyd M, Vijapur D, Sadow S, Wilkins D, Abe Y, Ikeda K, Kanegane H, Kano Z, Moriuchi H, Muneuchi J, Nishikomori R, Okazaki K, Takas T, Sakaguchi A, Villafana T.   +16 more
europepmc   +1 more source

Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab.

JAMA Netw Open
Acker KP, Strobino K, DeAngelis JM, Staniczenko AP, Son M, Riley LE, Han JY, Abramson EL, Grinspan ZM, Levine DA.   +9 more
europepmc   +1 more source